Hemophilia B clinical trials

Explore recruiting hemophilia b clinical trials.

Recruiting hemophilia b studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hemophilia B trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors (PRESent-3)

Spain, France, Italy, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects with Hemophilia B

Netherlands, Denmark, Belgium, Germany, Ireland, Sweden

Phase II and Phase III (Integrated) EU CTIS Study details

Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies.

Poland, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B

Belgium, Austria, France, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/CAS9-Based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B

Germany, France, Italy, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)

Spain, Germany, Belgium, Italy, France, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Hemophilia B trials by city

Hemophilia B in Toronto Hemophilia B in Vancouver Hemophilia B in Montreal Hemophilia B in Calgary Hemophilia B in Edmonton Hemophilia B in Ottawa Hemophilia B in Winnipeg Hemophilia B in Quebec City Hemophilia B in Hamilton Hemophilia B in Kitchener Hemophilia B in London Hemophilia B in Halifax Hemophilia B in New York Hemophilia B in Los Angeles Hemophilia B in Chicago Hemophilia B in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease